# Delta-Fly Pharma

Source: https://onco.cc/companies/delta-fly-pharma/  
OnCo record `delta-fly-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Delta-Fly is a small Japanese company from Tokushima that improves existing chemotherapy drugs; its continuous-infusion cytarabine analogue DFP-10917 is in phase 3 for relapsed acute myeloid leukaemia.

## Summary

Delta-Fly Pharma, based in Tokushima and listed in Tokyo, develops modified versions of established cytotoxic drugs. Its lead candidate DFP-10917, a deoxycytidine analogue given by continuous infusion, is in a phase 3 trial in relapsed or refractory acute myeloid leukaemia, and DFP-14323, an oral formulation of the protease inhibitor ubenimex, is tested in lung cancer. Its trials are registered on ClinicalTrials.gov under Delta-Fly as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Delta-Fly Pharma, Inc.; デルタフライファーマ
- Tags: ctgov-sponsor
- HQ: Tokushima
- Type: biotech
- Website: https://www.delta-flypharma.co.jp

## Sources

- Official website: https://www.delta-flypharma.co.jp
- ClinicalTrials.gov: trials led by Delta-Fly Pharma, Inc.: https://clinicaltrials.gov/search?lead=Delta-Fly%20Pharma%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q60997589

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/delta-fly-pharma.json